Gastric Cancer
Conditions
Keywords
gastric cancer, metastatic, docetaxel, cisplatin, S-1
Brief summary
The purpose of this study is to assess efficacy and safety of docetaxel alone, docetaxel plus cisplatin, and docetaxel plus S-1 in patients with metastatic gastric cancer after failing 1st line chemotherapy with cisplatin plus S-1 or capecitabine
Detailed description
To date, the most commonly used first-line chemotherapies have been based on fluorouracil and/or cisplatin in patients with metastatic gastric cancer. Unfortunately, considerable proportions of patients with metastatic gastric cancer do not respond to first-line chemotherapy and most of the patients who do respond eventually experience disease progression. In the second-line treatment, however, standard therapies are less clearly defined. Meanwhile, regarding re-challenge of previous failed drugs as a combination with an other newly introduced chemotherapeutic agent, there are few data. Increased expression and activity of thymidylate synthase, which is inhibited by fluoropyrimidine, is regarded to be the main reason for the development of clinical resistance to fluoropyrimidine. Since the cotreatment of docetaxel and 5-fluorouracil decreases the activity and expression of thymidylate synthase and dihydropyrimidine dehydrogenase (5-fluorouracil degradation enzyme), and increases the expression of orotate phosphoribosyl transferase, the addition of docetaxel into S-1 may recover the sensitivity to S-1 in patients previously resistant to S-1. Several reports found that MDR-1 and MRP-1 are related to cisplatin-resistance; cisplatin induces the overexpression of MRP-1, which reduces intracellular cisplatin accumulation. Since docetaxel suppresses the cisplatin-induced MRP-1 upregulation, the addition of docetaxel into cisplatin may recover the sensitivity to cisplatin in patients previously resistant to cisplatin. Based on these synergism mechanisms, we speculate that the cotreatment of docetaxel and cisplatin or S-1 has better anti-tumor activity than docetaxel alone in patients resistant to cisplatin or S-1.
Interventions
DRUGdocetaxel
docetaxel 75 mg/m2, IV on day 1 of each 3 week cycle until progression or unacceptable toxicity develops
docetaxel 60 mg/m2 and cisplatin 60 mg/m2, IV on day 1 of each 3 week cycle until progression or unacceptable toxicity develops
DRUGdocetaxel, S-1
docetaxel 60 mg/m2 IV on day 1 and S-1 30 mg/m2 bid PO on days 1-14 of each 3 week cycle until progression or unacceptable toxicity develops
Sponsors
Seoul National University Bundang Hospital
Chungbuk National University Hospital
Gachon University Gil Medical Center
National Cancer Center, Korea
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically confirmed gastric adenocarcinoma with metastatic disease * Age ≥18 years * Eastern Cooperative Oncology Group performance status 0-2 * At least one measurable lesion as defined by RECIST * Only one prior chemotherapy containing both S-1 or capecitabine and cisplatin for metastatic gastric cancer with documented progression of disease occurring during chemotherapy or within 6 months of completion of chemotherapy * Adequate major organ function: ANC ≥1,500/mm3, Platelet ≥100,000/mm3, serum bilirubin ≤1.5 x upper limit of normal (ULN), AST/ALT ≤2.5 x ULN (≤5 x ULN if liver metastases are present), creatinine clearance ≥50 ml/min using the calculation formula or 24 hours urine collection * Patients should sign a written informed consent before study entry
Exclusion criteria
* Prior taxane treatment * Major surgery or radiotherapy less than 4 weeks prior to entry * NCI CTCAE (version 3.0) adverse events ≥grade 2 except alopecia, fatigue, and weight loss * Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome, or inability to take oral medication * Patients with active gastrointestinal bleeding * Inadequate cardiovascular function * Serious concurrent infection or nonmalignant illness that is uncontrolled or whose control may be jeopardized by complications of study therapy * Other malignancy within the past 3 years except adequately treated non-melanomatous skin cancer, carcinoma in situ of the cervix, or in situ of prostate cancer Gleason≤7 * Psychiatric disorder that would preclude compliance * Patients receiving a concomitant treatment with drugs interacting with S-1 such as flucytosine, phenytoin, or allopurinol * Female patients who are pregnant or breast feeding or adults of reproductive potential not employing effective method of birth control
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| response rate | every 2 cycles |
Secondary
| Measure | Time frame |
|---|---|
| time to progression | every 2 cycles |
Countries
South Korea
Contacts
Primary ContactSook Ryun Park, Dr.
Backup ContactYoung Lan Park, CRC
Outcome results
None listed